Using PredicineCARE™ to analyze TP53 mutations in cell-free DNA from patients with metastatic breast cancer to investigate disease characteristics and the prognostic role of different locations of the TP53 mutation site.
April 2021
Read morePTEN-PI3K-AKT pathway CNVs were detected using Predicine’s cfDNA liquid biopsy assay, with the prevalence of PTEN loss comparable with tissue-based studies. Plasma cfDNA profiling may facilitate and optimize patient selection for targeted treatment with Akt inhibitors in mCRPC.
April 2021
Read moreUsing PredicineCARE™ to analyze mutational landscape of 158 tumor related genes in HER2-positive breast cancer patients.
November 2020
Read moreUsing PredicineCARE™ to detect CXCR4 mutations in bone marrow samples of Waldenström macroglobulinemia patients for patient stratification.
November 2020
Read moreThe first prospective observational clinical study that simultaneously investigates cfDNA and cfRNA focusing on AR biomarkers in two independent mCRPC cohorts.
May 2020
Read moreAn editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.
May 2020
Read moreUsing Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from mSHPC to mCRPC. Gene deletion and amplification of BRCA, PTEN, RB, AR are reported.
April 2020
Read moreUsing Predicine’s cfDNA assay to analyze the relationship between BRCA gene status and the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced TNBC.
February 2020
Read moreValidation of Predicine’s ctDNA assay reporting high concordance of variant detection in orthogonal samples between Predicine and Guardant Health’s ctDNA platforms.
January 2020
Read moreThe potential of combining CTCs and ctDNA for comprehensive liquid biopsy analysis to accurately represent genomic heterogeneity with implications for clinical management of patients with MBC.
December 2019
Read more• Validation of Predicine’s tissue-agnostic MRD assay that detects cancer variants down to 0.005%.
April 2021
View Poster
• Predicine’s LP-WGS assay for identification of segment-based CNVs and CNV abnormality in plasma samples from 500 cancer patients, including breast, prostate, pancreatic and lung cancers.
April 2021
View Poster
• Predicine’s enzyme-controlled methylation assay demonstrates dramatic improvement over WGBS in reducing DNA damage and GC bias as well as increasing NGS reads mapping rate and mapping quality score.
April 2021
View Poster
• Validation of PredcineCARE™’s ability to detect gene copy number loss (PTEN) in low fraction of tumor contents in plasma of prostate cancer patients.
April 2021
View Poster
• Simultaneous profiling of Androgen Receptor splicing variants, hotspot mutations and amplifications at both cfDNA and cfRNA levels.
February 2021
View Poster
• Urine-based liquid biopsy treatment selection, disease monitoring, and early cancer detection in bladder cancer
February 2021
View Poster
• Blood TMB towards personalized anti-PD-1 immunotherapy (toripalimab) in metastatic urothelial carcinoma
February 2021
View Poster
• Blood-based detection of copy number variations (CNVs) in the PTEN-PI3K-AKT and AR pathway
• PTEN copy number loss
February 2021
View Poster
• PredicineATLAS™ to assess germline mutations in breast cancer populations with different clinical features.
• Large cohort study to support the development of precision oncology therapies for breast cancer patients.
December 2020
View Poster
• Calibration and validation of bTMB platforms to help harmonization between panels and laboratories thus improving the accuracy of testing to aid treatment decisions in oncology
• PredicineATLAS™ to assess bTMB
• Collaboration with AstraZeneca 
November 2020
• ctDNA changes correlate with ORR in BTC patients treated with durvalumab + tremelimumab immunotherapy
• Collaboration with AstraZeneca
May 2020
View Poster
• ctDNA and cfRNA profiling, TMB
• Matched plasma and tissue
• Collaboration with Merck KGaA and EMD Serono
January 2020
View Poster
• Methylation profiling in plasma cfDNA and urinary cfDNA
• PredicineMETHYLATION™
• Early cancer detection
June 2020
View Poster
• ctDNA profiling for AR mutation and amplification
• cfRNA profiling for AR-V7 splicing variants
• Therapy response and drug resistance
January 2020
View Poster
• PTEN-PI3K, AR, DDR pathway alterations
• Mono- vs. bi-allelic gene deletion in BRCA, PTEN
• cfRNA-based detection of fusions and splice variants
January 2019
View Poster
Lorenzo Gerratana, Qiang Zhang, Andrew A Davis, Ami N Shah, Jianjun Yu, Shidong Jia, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradisha, and Massimo Cristofanilli
December 2019
Read more
Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli
December 2019
Read more
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee
June 2019
Read more
Heidi Fettke, Edmond M. Kwan, Jianjun Yu, Amy Wang, Carlos Montesinos, Calvin Wong, Xue Gong, Tiantian Zheng, Peter Pan Du, Shidong Jia, Andrew Mant, Phillip Parente, Carmel Pezaro, Arun A. Azad
April 2019
Read more
Zhixin Zhao, Amy Chang, Tak Cheung, Feng Xie, Carlos Montesinos, Amy Xiaohong Wang, Kemin Zhou, Shidong Jia, JIanjun Yu, Pan Du
April 2019
Read more
Manish Kohli, Siddhartha Yadav, Winston Tan, Irbaz Bin Riaz, Tiantian Zheng, Amy Wang, Carlos Montesinos, Calvin Wong, Peter Du, Shidong Jia, Jianjun Yu
February 2019
Read more
Ready to streamline your precision oncology clinical research programs? Submit your information to speak to a team member.